

**N-Terminal PRO B-Type Natriuretic Peptide  
Levels in Neonates with Patent Ductus  
Arteriosus and Their Modulation  
by Treatment**

**Thesis**

Submitted for Partial Fulfillment of Master Degree  
in Pediatrics

*By*

**Ali Elsayed Ahmed**  
M.B.B.Ch.

*Under the Supervision of*  
Professor Dr.

Tarek Ahmed Abd Elgawad  
Professor of Pediatrics  
Faculty of Medicine – Ain Shams University

Dr.

Ola Abd Elaziz Elmasry  
Assistant Professor of Pediatrics  
Faculty of Medicine – Ain Shams University

Dr.

Eman Saleh Elhadidi  
Assistant Professor of Clinical Pathology  
Faculty of Medicine – Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2010**



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة الآية (32)

## *Acknowledgement*

Firstly, I wish to express my deep thanks to **ALLAH**, by the grace of whom the progress and completion of the present work was made possible.

I am greatly indebted to **Prof. Tarek Ahmed Abd Elgawad** Professor of Pediatric, Faculty of Medicine, Ain Shams University for his unfailing encouragement, sincere guidance, valuable suggestion, constructive opinions throughout the whole work and his everlasting patience.

I would like to express my deep gratitude and appreciation to **Dr. Ola Abd Elaziz Elmasry** Assistant Professor of Pediatric, Faculty of Medicine, Ain Shams University for her scientific insight, kind supervision, precious advice, and unlimited help to accomplish this work.

Special thanks are owed to **Dr. Eman Saleh Elhadidi** Assistant Professor of Biochemistry, Faculty of Medicine, Ain Shams University for his help regarding the laboratory part of the work. I am also grateful to him for graciously lending a hand whenever needed all over the stages of the work.

**Ali Elsayed**

# *List of Contents*

<i>Title</i>	<i>Page No.</i>
Introduction .....	1
Aim of the work .....	3
Review of literature:	
○ Patent ductus arteriosus (PDA) .....	4
○ Review of literature NTerminal-pro B-Type Brain Natreurtic Peptidep(NT-proBNP) .....	65
Patients and Methods .....	81
Results .....	91
Discussion .....	139
Summary .....	148
Conclusion .....	150
Recommendation .....	151
References .....	152
Arabic Summary .....	---



# List of Figures

<i>Figure No.</i>	<i>Name</i>	<i>Page</i>
1	Patent ductus arteriosus .....	4
2	Development of aortic arches .....	6
3	Cross-section of term PDA .....	7
4	Fetal circulation .....	12
5	X ray of a baby with a large duct .....	33
6	M mode view showing the left atrial: aortic root ratio .....	35
7	The "3-legged stool" echo view of the ductus .....	36
8	Widely patent ductal arch in fetal life .	37
9	Parasternal long axis view with left atrial and ventricular dilation .....	37
10	Continuous Doppler with diastolic flow from ductus in pulmonary artery .....	38
11	Pulsed Doppler in the duct with different types .....	38
12	Color Doppler ductus flow .....	40
13	Large patent arterial duct in left ventriculogram .....	43

14	Tornado-like ductus in MRI .....	44
15	MRI of PDA .....	44
16	The Amplatzer duct occluder .....	62
17	Photograph of Gianturco coil .....	63
18	The devices used for transcatheter closure of PDA .....	63
19	The Botallooccluder .....	64
20	Structure of NPs .....	65
21	The structures of proBNP, NT-proBNP and BNP .....	66
22	Action of BNP at Target Cells .....	69
23	The details of the progress of the study .....	89
24	Comparison between patients and controls regarding gestational age, age, birth weight and maternal age .....	92
25	Distribution of the studied group according to gender and mode of delivery .....	94
26	Comparison between patients and controls regarding APGAR score at I minute and 5 minute .....	96
27	Comparison between patients and controls regarding heart rate, systolic blood pressure .....	98

28	Comparison between patients and controls regarding diastolic blood pressure, pulse pressure and capillary refill time .....	98
29	Comparison between patients and controls regarding platelets and sodium	100
30	Comparison between patients and controls regarding urea and creatinin ...	100
31	Comparison between patients and controls regarding pH, PCO <sub>2</sub> and HCO <sub>3</sub>	102
32	Comparison between patients and controls regarding NT-proBNP .....	104
33	Comparison between patients and controls regarding LA/AO ratio .....	104
34	Comparison between patients before treatment and patients after treatment regarding systolic BP,DBP and pulse pressure .....	108
35	Comparison between patients before treatment and patients after treatment regarding NT-proBNP .....	110
36	Comparison between patients before treatment and patients after treatment regarding LA/AO ratio and duct size .....	111
37	Effect of indomethacin on ductal closure in patients .....	113



38	Comparison between patients before treatment and patients after treatment regarding NT-proBNP .....	115
39	Comparison between patients before treatment and patients after treatment regarding ductal size .....	117
40	Comparison between patients before treatment and patients after treatment regarding platelets, urea, Na and K .....	119
41	Comparison between patients before treatment and patients after treatment regarding hematocrite and creatinin .....	120
42	Comparison between patients before treatment and patients after treatment regarding pH, PCO <sub>2</sub> and HCO <sub>3</sub> .....	122
43	Percentage of patients with sPDA which complicated with sepsis and those with no sepsis .....	125
44	Comparison between patients with sepsis and patients with no sepsis regarding heart rate and platelets .....	127
45	Comparison between patients with sepsis and patients with no sepsis regarding gestational age, birth weight SBP,DBP and pulse pressure .....	128

46	Comparison between patients with sepsis and patients with no sepsis regarding NT-proBNP .....	128
47	Comparison between patients with sepsis and patients with no sepsis regarding LA/AO raio and duct size .....	129
48	Percentage of deaths and survivors in patients with PDA .....	131
49	Comparison between deaths and survivors regarding age, birth weigh and creatinin .....	133
50	Comparison between deaths and survivors regarding gestational age SBP and DBP .....	134
51	Comparison between deaths and survivors regarding NT-proBNP .....	136
52	Comparison between deaths and survivors regarding LA/AO ratio and duct size .....	136
53	ROC for determination of NT-proBNP cutoff value .....	137

## *List of Tables*

<i>Table No.</i>	<i>Name</i>	<i>Page</i>
1	Doses of digoxin in neonates .....	54
2	Indomethacin dosage .....	55
3	Characteristics of B-type natriuretic peptide (BNP) and NT-proBNP .....	67
4	Number of patients with different clinical signs of BDA .....	86
5	Gestational age, age and weight in patients and controls .....	91
6	Gender and mode of delivery in studied groups .....	93
7	Comparison between patients and controls as regard APGAR score at 1 minute and 5 minute .....	95
8	Comparison between patients and controls as regard heart rate, systolic blood pressure, diastolic blood pressure, pulse pressure and capillary refill time .....	97
9	Comparison between patients and controls as regard Haematocrit, platelet count, urea, creatinin, sodium and potassium .....	99

10	Comparison between patients and controls as regard pH, PCO <sub>3</sub> and bicarbonate levels in capillary blood gases .....	101
11	Comparison between patients and controls as regard NT-proBNP and LA/AO ratio ....	103
12	Relation between gestational age and NT-proBNP before treatment with Indomethacin .....	105
13	Relation between LA/AO and Nt-proBNP before treatment wit indomethcin .....	105
14	Relation between ductus arteriosus size and Nt-proBNP before treatment with indomethcin .....	105
15	Relation between urea levels and Nt-proBNP before treatment with indomethcin .....	106
16	Relation between LA/AO ratio and ductal size .....	106
17	Comparison between patients before treatment with indomethacin and after treatment as regard heart rate, systolic blood pressure, diastolic blood pressure and pulse pressure .....	107
18	Comparison between patients before and after treatment with indomethacin as regard NT-proBNP level, LA/AO ratio and duct size .....	109

19	Effects of one dose of indomethacin on ductal closure .....	112
20	Comparison between patients with successful closure and patients with failed closure regarding mean values of NT-pro BNP .....	114
21	Comparison between patients with successful closure and patients with failed closure regarding mean values of ductal size .....	116
22	Comparison between patients before and after treatment with indomethacin as regard Haematocrit, platelet count, urea, creatinin, Na and potassium levels .....	118
23	Comparison between patients before and after treatment with indomethacin as regard PH, PCO <sub>2</sub> and HCO <sub>3</sub> in capillary blood gases .....	121
24	Correlation between NT-proBNP and birth weight, systolic blood pressure and pulse pressure .....	123
25	Percentage of patients with PDA complicated with sepsis and those not complicated with sepsis .....	124
26	Comparison between patients with sepsis and patients with no sepsis .....	126

27	Distribution of death and survival in patients with PDA .....	130
28	Comparison between deaths and survivors as regard mean values of gestational age, age, birth weight, systolic and diastolic blood pressure and creatinine .....	132
29	Comparison between deaths and survivors as regarding mean values on NT-proBNP, / LA/AO and duct size .....	135
30	Sensitivity, Specificity, PPV, NPV and diagnostic ability of NT-proBNP .....	138

## *List of Abbreviations*

<b>ADO</b> .....	Amplatzer duct occluder
<b>ANP</b> .....	Atrial natriuretic peptide
<b>AO</b> .....	Aorta
<b>ASD</b> .....	Atrial septal defect
<b>AUC</b> .....	Area under curve
<b>BNP</b> .....	Brain natriuretic peptide
<b>BPD</b> .....	Brochopulmonary dysplasia
<b>CBF</b> .....	Cerebral blood flow
<b>cGMP</b> .....	Cyclic guanine monophosphate
<b>CHF</b> .....	Congestive heart failure
<b>CNP</b> .....	C type natriuretic peptide
<b>CPAP</b> .....	Continuous positive airway pressure
<b>DA</b> .....	Ductus arteriosus
<b>DNA</b> .....	Deoxyribonucleic acid
<b>DNP</b> .....	Dendroaspis natriuretic peptide
<b>ECG</b> .....	Electro-cardiogram
<b>EDV</b> .....	End diastolic volume
<b>EEG</b> .....	Electro-encephalogram
<b>EF</b> .....	Ejection fraction
<b>EIA</b> .....	Enzyme immunoassay
<b>ELBW</b> .....	Extremely low birth weight